Xu-Monette et al. have shown a predictive role for TP53 in both the GCB and non-GCB DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) [9]. Here, TP53 is linked to diffuse large B-cell lymphoma.